UK Looks To Switch Overactive Bladder Treatment
Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.
Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.